Taltz — Revenue
Eli Lilly Taltz — Revenue decreased by 30.3% to $733.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $762.00M to $733.00M. Over 4 years (FY 2021 to FY 2025), Taltz — Revenue shows an upward trend with a 12.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful penetration in the immunology therapeutic market, while a decrease may signal increased competition from biosimilars or newer treatment alternatives.
Detailed definition
This metric represents the total gross sales generated from the Taltz product line, which is an immunology therapeutic u...
Peer comparison
Comparable to revenue metrics for specific blockbuster immunology drugs at peer pharmaceutical companies, often evaluated against market share in the psoriasis and spondyloarthritis segments.
lly_segment_taltz_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $569.10M | $593.10M | $647.40M | $488.10M | $606.20M | $679.90M | $707.80M | $527.00M | $703.90M | $744.20M | $785.00M | $604.10M | $824.70M | $879.60M | $951.60M | $762.00M | $847.60M | $901.50M | $1.05B | $733.00M |
| QoQ Change | — | +4.2% | +9.2% | -24.6% | +24.2% | +12.2% | +4.1% | -25.5% | +33.6% | +5.7% | +5.5% | -23.0% | +36.5% | +6.7% | +8.2% | -19.9% | +11.2% | +6.4% | +16.7% | -30.3% |
| YoY Change | — | — | — | — | +6.5% | +14.6% | +9.3% | +8.0% | +16.1% | +9.5% | +10.9% | +14.6% | +17.2% | +18.2% | +21.2% | +26.1% | +2.8% | +2.5% | +10.6% | -3.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's taltz — revenue?
- Eli Lilly (LLY) reported taltz — revenue of $733.00M in Q1 2026.
- How has Eli Lilly's taltz — revenue changed year-over-year?
- Eli Lilly's taltz — revenue decreased by 3.8% year-over-year, from $762.00M to $733.00M.
- What is the long-term trend for Eli Lilly's taltz — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's taltz — revenue has grown at a 12.6% compound annual growth rate (CAGR), from $2.21B to $3.56B.
- What does taltz — revenue mean?
- The total revenue generated from sales of the Taltz immunology medication.